Quarterly Activities/Appendix 4C Cash Flow Report

• Successfully manufactured and released first two batches of ALA-101 for clinical use
• First patient dosing in clinical trial expected this month
• Received $4.03 million R&D tax incentive rebate, boosting cash position to $15.63 million

Arovella Therapeutics Ltd. has made significant strides in its clinical and preclinical programs, culminating in the release of two batches of its lead product, ALA-101, for clinical use. The company activated two clinical trial sites and expects to dose the first patient this month. Additionally, Arovella received a $4.03 million R&D tax incentive rebate, enhancing its cash position to approximately $15.63 million as of the end of Q4 FY26. The company remains focused on generating initial clinical data from ALA-101, which is being tested in patients with relapsed or refractory CD19-positive non-Hodgkin lymphoma and certain leukaemias.

Arovella aims to demonstrate the potential of ALA-101 in blood cancers and expand into solid tumours and autoimmune diseases. The company is preparing regulatory filings and initiating IND-enabling activities for ALA-105.